Literature DB >> 4023247

Malignant melanoma of the eye: treatment of posterior uveal lesions by Co-60 plaque radiotherapy versus enucleation.

A M Markoe, L W Brady, J A Shields, J J Augsburger, B Micaily, J I Damsker, J L Day, J W Gamel.   

Abstract

Survival rates and visual acuity of 100 patients treated for posterior uveal malignant melanoma by cobalt-60 plaque radiotherapy were compared with 150 patients treated by enucleation for the same disease. Life-table comparisons of the entire group showed significant differences in survival rates, with plaque radiotherapy patients appearing to fare better. However, when patients with small or medium tumors were compared, only slight differences were seen, implying that criteria used to select patients for treatment may affect interpretation. The two groups were also compared using the Cox proportional hazards model, which predicts survival based on the impact of clinical variables. In this analysis, the survival rates of the plaque radiotherapy group were no worse than those of the enucleation group. The advantage of conservative therapy lies in the potential to preserve useful vision over a considerable time. Because patients were specifically selected for treatment modality and because the study size used to calibrate the Cox model was small, the results of this study must be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023247     DOI: 10.1148/radiology.156.3.4023247

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

1.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

2.  The radiosensitivity of uveal melanoma cells and the cell survival curve.

Authors:  D Soulières; A Rousseau; M Tardif; M Larochelle; M Tremblay; L Vaillancourt; G Pelletier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-02       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.